129 related articles for article (PubMed ID: 9845393)
1. Monitoring adverse drug events: the Food and Drug Administration MedWatch reporting system.
Landow L
Reg Anesth Pain Med; 1998; 23(6 Suppl 2):190-3. PubMed ID: 9845393
[No Abstract] [Full Text] [Related]
2. Statistics: detecting a rare adverse drug reaction using spontaneous reports.
Schroeder DR
Reg Anesth Pain Med; 1998; 23(6 Suppl 2):183-9. PubMed ID: 9845392
[No Abstract] [Full Text] [Related]
3. FDA public health advisory: low molecular-weight heparin and spinal/epidural anesthesia or spinal puncture.
Lumpkin MM
Int J Trauma Nurs; 1998; 4(2):56-7. PubMed ID: 9855967
[No Abstract] [Full Text] [Related]
4. MedWatch program.
White GG
Int J Trauma Nurs; 1998; 4(3):100-3. PubMed ID: 9855977
[No Abstract] [Full Text] [Related]
5. Neuraxial block and low-molecular-weight heparin: balancing perioperative analgesia and thromboprophylaxis.
Horlocker TT; Wedel DJ
Reg Anesth Pain Med; 1998; 23(6 Suppl 2):164-77. PubMed ID: 9845390
[No Abstract] [Full Text] [Related]
6. Spinal and epidural blockade and perioperative low molecular weight heparin: smooth sailing on the Titanic.
Horlocker TT; Wedel DJ
Anesth Analg; 1998 Jun; 86(6):1153-6. PubMed ID: 9620494
[No Abstract] [Full Text] [Related]
7. MEDWatch: the new FDA medical products reporting program.
Kessler DA
Am J Hosp Pharm; 1993 Jun; 50(6):1151-2. PubMed ID: 8517452
[No Abstract] [Full Text] [Related]
8. Monitoring drug product quality.
Bolger G; Goetsch R; Reinstein P
Am Pharm; 1992 Feb; NS32(2):47-9. PubMed ID: 1546630
[No Abstract] [Full Text] [Related]
9. The prescription drug user fee act: active postmarketing drug surveillance and safety.
Lyles A
Clin Ther; 2002 May; 24(5):800-2. PubMed ID: 12075947
[No Abstract] [Full Text] [Related]
10. Low molecular weight heparin for thromboprophylaxis and epidural/spinal anaesthesia--is there a risk?
Bergqvist D; Lindblad B; Mätzsch T
Acta Anaesthesiol Scand; 1992 Oct; 36(7):605-9. PubMed ID: 1332355
[TBL] [Abstract][Full Text] [Related]
11. FDA public health advisory.
Lumpkin MM
Anesthesiology; 1998 Feb; 88(2):27A-28A. PubMed ID: 9477044
[No Abstract] [Full Text] [Related]
12. Adverse drug reactions and reporting.
Witte R
Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
[No Abstract] [Full Text] [Related]
13. MedWatch. On lookout for medical product problems.
Ropp KL
FDA Consum; 1993 Nov; 27(9):14-7. PubMed ID: 10130376
[No Abstract] [Full Text] [Related]
14. FDA's monitoring of postmarketing studies probed.
Young D
Am J Health Syst Pharm; 2006 Aug; 63(16):1485-6. PubMed ID: 16896075
[No Abstract] [Full Text] [Related]
15. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
16. Low-molecular weight heparin, spinal hematomas, and the FDA: what's wrong with this picture?
Landow L; Bedford RA
Reg Anesth Pain Med; 1999; 24(1):8-10. PubMed ID: 9952088
[No Abstract] [Full Text] [Related]
17. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.
Kessler DA
JAMA; 1993 Jun; 269(21):2765-8. PubMed ID: 8492403
[No Abstract] [Full Text] [Related]
18. When you suspect epidural hematoma.
Stillwell SB
Am J Nurs; 2000 Sep; 100(9):68-70, 72, 74 passim. PubMed ID: 11002797
[No Abstract] [Full Text] [Related]
19. From the Food and Drug Administration.
Nightingale SL
JAMA; 1998 Feb; 279(5):346. PubMed ID: 9459455
[No Abstract] [Full Text] [Related]
20. MedWatch targets reporting of serious adverse events.
VanAmringe M
Jt Comm Perspect; 1993; 13(4):15. PubMed ID: 10129237
[No Abstract] [Full Text] [Related]
[Next] [New Search]
